Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.
The test, which was developed by Cleveland Clinic researcher Robert Fairchild and University of Alabama researchers Roslyn Mannon, identifies RNA molecules in urine that are highly accurate for the diagnosis of rejection and elevated risk of rejection in kidney transplant patients. The partners are aiming to give clinicians a way to diagnose clinical acute rejection without a biopsy and to distinguish clinical acute rejection from other non-rejection causes of kidney dysfunction after transplant.
Eurofins Viracor said it will work with Fairchild to validate the diagnostic assay for use in patient testing.
Further terms of the deal were not disclosed.